FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:AHR-CDK14

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: AHR-CDK14
FusionPDB ID: 3134
FusionGDB2.0 ID: 3134
HgeneTgene
Gene symbol

AHR

CDK14

Gene ID

196

5218

Gene namearyl hydrocarbon receptorcyclin dependent kinase 14
SynonymsRP85|bHLHe76PFTAIRE1|PFTK1
Cytomap

7p21.1

7q21.13

Type of geneprotein-codingprotein-coding
Descriptionaryl hydrocarbon receptorAH-receptorah receptoraromatic hydrocarbon receptorclass E basic helix-loop-helix protein 76cyclin-dependent kinase 14PFTAIRE protein kinase 1cell division protein kinase 14serine/threonine-protein kinase PFTAIRE-1
Modification date2020032220200313
UniProtAcc

A9YTQ3

Main function of 5'-partner protein: FUNCTION: Mediates dioxin toxicity and is involved in regulation of cell growth and differentiation. Represses the transcription activity of AHR by competing with this transcription factor for heterodimer formation with the ARNT and subsequently binding to the xenobiotic response element (XRE) sequence present in the promoter regulatory region of variety of genes. Represses CYP1A1 by binding the XRE sequence and recruiting ANKRA2, HDAC4 and/or HDAC5. Autoregulates its expression by associating with its own XRE site. {ECO:0000269|PubMed:17890447, ECO:0000269|PubMed:18172554}.

O94921

Main function of 5'-partner protein: FUNCTION: Serine/threonine-protein kinase involved in the control of the eukaryotic cell cycle, whose activity is controlled by an associated cyclin. Acts as a cell-cycle regulator of Wnt signaling pathway during G2/M phase by mediating the phosphorylation of LRP6 at 'Ser-1490', leading to the activation of the Wnt signaling pathway. Acts as a regulator of cell cycle progression and cell proliferation via its interaction with CCDN3. Phosphorylates RB1 in vitro, however the relevance of such result remains to be confirmed in vivo. May also play a role in meiosis, neuron differentiation and may indirectly act as a negative regulator of insulin-responsive glucose transport. {ECO:0000269|PubMed:16461467, ECO:0000269|PubMed:17517622, ECO:0000269|PubMed:19524571, ECO:0000269|PubMed:20059949}.
Ensembl transtripts involved in fusion geneENST idsENST00000242057, ENST00000492120, 
ENST00000496279, ENST00000265741, 
ENST00000380050, ENST00000406263, 
ENST00000436577, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score6 X 5 X 5=15022 X 24 X 12=6336
# samples 832
** MAII scorelog2(8/150*10)=-0.906890595608519
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(32/6336*10)=-4.30742852519225
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: AHR [Title/Abstract] AND CDK14 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: AHR [Title/Abstract] AND CDK14 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)AHR(17338953)-CDK14(90741857), # samples:2
Anticipated loss of major functional domain due to fusion event.AHR-CDK14 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
AHR-CDK14 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneAHR

GO:0006355

regulation of transcription, DNA-templated

10395741

HgeneAHR

GO:0006357

regulation of transcription by RNA polymerase II

15681594

HgeneAHR

GO:0006366

transcription by RNA polymerase II

10395741

HgeneAHR

GO:0009410

response to xenobiotic stimulus

7961644

HgeneAHR

GO:0009636

response to toxic substance

7961644

HgeneAHR

GO:0010468

regulation of gene expression

15681594

HgeneAHR

GO:0019933

cAMP-mediated signaling

17329248

HgeneAHR

GO:0030888

regulation of B cell proliferation

15681594

HgeneAHR

GO:0071320

cellular response to cAMP

17329248

HgeneAHR

GO:1904322

cellular response to forskolin

17329248

HgeneAHR

GO:1904613

cellular response to 2,3,7,8-tetrachlorodibenzodioxine

17329248

TgeneCDK14

GO:0000086

G2/M transition of mitotic cell cycle

20059949

TgeneCDK14

GO:0060828

regulation of canonical Wnt signaling pathway

20059949



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:17338953/chr7:90741857)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across AHR (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across CDK14 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000242057AHRchr717338953+ENST00000380050CDK14chr790741857+44187087261242
ENST00000242057AHRchr717338953+ENST00000265741CDK14chr790741857+44177087261242
ENST00000242057AHRchr717338953+ENST00000406263CDK14chr790741857+4413708502963153
ENST00000242057AHRchr717338953+ENST00000436577CDK14chr790741857+11907087261242

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000242057ENST00000380050AHRchr717338953+CDK14chr790741857+0.0468012430.9531987
ENST00000242057ENST00000265741AHRchr717338953+CDK14chr790741857+0.0673946740.9326054
ENST00000242057ENST00000406263AHRchr717338953+CDK14chr790741857+0.075158990.92484105
ENST00000242057ENST00000436577AHRchr717338953+CDK14chr790741857+0.067595880.93240416

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for AHR-CDK14

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
AHRchr717338953CDK14chr79074185770869YASRKRRKPVQKTLSYVNHAEDLASK

Top

Potential FusionNeoAntigen Information of AHR-CDK14 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
AHR-CDK14_17338953_90741857.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
AHR-CDK14chr717338953chr790741857708HLA-B52:01VQKTLSYV0.97590.799917
AHR-CDK14chr717338953chr790741857708HLA-B27:04RRKPVQKTL0.99960.7285514
AHR-CDK14chr717338953chr790741857708HLA-B27:05RRKPVQKTL0.99950.791514
AHR-CDK14chr717338953chr790741857708HLA-B35:01KPVQKTLSY0.9920.6441716
AHR-CDK14chr717338953chr790741857708HLA-B35:08KPVQKTLSY0.98510.5952716
AHR-CDK14chr717338953chr790741857708HLA-B15:25KPVQKTLSY0.97720.7457716
AHR-CDK14chr717338953chr790741857708HLA-B15:02KPVQKTLSY0.97560.7437716
AHR-CDK14chr717338953chr790741857708HLA-B14:02RRKPVQKTL0.95070.8416514
AHR-CDK14chr717338953chr790741857708HLA-B14:01RRKPVQKTL0.95070.8416514
AHR-CDK14chr717338953chr790741857708HLA-A02:21KTLSYVNHA0.94840.71591120
AHR-CDK14chr717338953chr790741857708HLA-A30:08KTLSYVNHA0.94290.64781120
AHR-CDK14chr717338953chr790741857708HLA-B35:04KPVQKTLSY0.18730.7113716
AHR-CDK14chr717338953chr790741857708HLA-B35:02KPVQKTLSY0.18730.7113716
AHR-CDK14chr717338953chr790741857708HLA-B27:05KRRKPVQKTL0.99950.729414
AHR-CDK14chr717338953chr790741857708HLA-B27:04KRRKPVQKTL0.99920.7509414
AHR-CDK14chr717338953chr790741857708HLA-B15:02RKPVQKTLSY0.85420.8926616
AHR-CDK14chr717338953chr790741857708HLA-B15:03RKPVQKTLSY0.81360.6433616
AHR-CDK14chr717338953chr790741857708HLA-B35:01RKPVQKTLSY0.78910.7558616
AHR-CDK14chr717338953chr790741857708HLA-B35:08RKPVQKTLSY0.78450.6882616
AHR-CDK14chr717338953chr790741857708HLA-B27:05RRKPVQKTLSY10.7342516
AHR-CDK14chr717338953chr790741857708HLA-B27:04RRKPVQKTLSY0.99990.6699516
AHR-CDK14chr717338953chr790741857708HLA-B27:04RKRRKPVQKTL0.99970.5799314
AHR-CDK14chr717338953chr790741857708HLA-B27:05RKRRKPVQKTL0.99970.5707314
AHR-CDK14chr717338953chr790741857708HLA-B27:14RRKPVQKTL0.99950.7437514
AHR-CDK14chr717338953chr790741857708HLA-C07:05RRKPVQKTL0.99760.9576514
AHR-CDK14chr717338953chr790741857708HLA-C07:95RRKPVQKTL0.99740.6815514
AHR-CDK14chr717338953chr790741857708HLA-C07:27RRKPVQKTL0.99580.9603514
AHR-CDK14chr717338953chr790741857708HLA-C07:29RRKPVQKTL0.99180.9465514
AHR-CDK14chr717338953chr790741857708HLA-B15:31KPVQKTLSY0.99160.6219716
AHR-CDK14chr717338953chr790741857708HLA-C07:13RRKPVQKTL0.98980.9355514
AHR-CDK14chr717338953chr790741857708HLA-C07:46RRKPVQKTL0.98570.9062514
AHR-CDK14chr717338953chr790741857708HLA-C07:19RRKPVQKTL0.97630.7542514
AHR-CDK14chr717338953chr790741857708HLA-B15:21KPVQKTLSY0.97610.727716
AHR-CDK14chr717338953chr790741857708HLA-C07:80RRKPVQKTL0.97260.9553514
AHR-CDK14chr717338953chr790741857708HLA-C07:67RRKPVQKTL0.97260.9553514
AHR-CDK14chr717338953chr790741857708HLA-C07:10RRKPVQKTL0.97220.9499514
AHR-CDK14chr717338953chr790741857708HLA-B27:03RRKPVQKTL0.95390.8135514
AHR-CDK14chr717338953chr790741857708HLA-B39:12RRKPVQKTL0.8390.8532514
AHR-CDK14chr717338953chr790741857708HLA-B14:03RRKPVQKTL0.61530.798514
AHR-CDK14chr717338953chr790741857708HLA-C07:27KPVQKTLSY0.36040.8772716
AHR-CDK14chr717338953chr790741857708HLA-B35:12KPVQKTLSY0.18730.7113716
AHR-CDK14chr717338953chr790741857708HLA-C12:16RRKPVQKTL0.1550.9688514
AHR-CDK14chr717338953chr790741857708HLA-C03:14KPVQKTLSY0.12620.9178716
AHR-CDK14chr717338953chr790741857708HLA-B27:14KRRKPVQKTL0.99950.6681414
AHR-CDK14chr717338953chr790741857708HLA-C07:05KRRKPVQKTL0.98070.9092414
AHR-CDK14chr717338953chr790741857708HLA-B27:03KRRKPVQKTL0.96590.75414
AHR-CDK14chr717338953chr790741857708HLA-B27:14RRKPVQKTLSY0.99990.6121516
AHR-CDK14chr717338953chr790741857708HLA-C07:95RRKPVQKTLSY0.99960.5518516
AHR-CDK14chr717338953chr790741857708HLA-C07:27RRKPVQKTLSY0.99940.9374516
AHR-CDK14chr717338953chr790741857708HLA-B27:03RRKPVQKTLSY0.99940.7513516
AHR-CDK14chr717338953chr790741857708HLA-C07:05RRKPVQKTLSY0.99940.9453516
AHR-CDK14chr717338953chr790741857708HLA-C07:19RRKPVQKTLSY0.99740.616516
AHR-CDK14chr717338953chr790741857708HLA-C07:67RRKPVQKTLSY0.99720.9233516
AHR-CDK14chr717338953chr790741857708HLA-C07:80RRKPVQKTLSY0.99720.9233516
AHR-CDK14chr717338953chr790741857708HLA-C07:10RRKPVQKTLSY0.99470.9352516
AHR-CDK14chr717338953chr790741857708HLA-C07:46RRKPVQKTLSY0.99240.8257516
AHR-CDK14chr717338953chr790741857708HLA-C12:16RRKPVQKTLSY0.95320.9479516
AHR-CDK14chr717338953chr790741857708HLA-B35:11PVQKTLSY0.95520.7198816
AHR-CDK14chr717338953chr790741857708HLA-B35:24PVQKTLSY0.8730.6071816
AHR-CDK14chr717338953chr790741857708HLA-B27:10RRKPVQKTL0.99960.8594514
AHR-CDK14chr717338953chr790741857708HLA-B27:06RRKPVQKTL0.99960.7084514
AHR-CDK14chr717338953chr790741857708HLA-B27:08RRKPVQKTL0.99950.6873514
AHR-CDK14chr717338953chr790741857708HLA-B27:09RRKPVQKTL0.99920.7474514
AHR-CDK14chr717338953chr790741857708HLA-C07:01RRKPVQKTL0.99850.7072514
AHR-CDK14chr717338953chr790741857708HLA-B35:77KPVQKTLSY0.9920.6441716
AHR-CDK14chr717338953chr790741857708HLA-B35:23KPVQKTLSY0.99130.5909716
AHR-CDK14chr717338953chr790741857708HLA-B35:20KPVQKTLSY0.99050.7271716
AHR-CDK14chr717338953chr790741857708HLA-C07:17RRKPVQKTL0.99040.9671514
AHR-CDK14chr717338953chr790741857708HLA-B15:39KPVQKTLSY0.97950.5719716
AHR-CDK14chr717338953chr790741857708HLA-B35:11KPVQKTLSY0.97470.6909716
AHR-CDK14chr717338953chr790741857708HLA-C07:02RRKPVQKTL0.97260.9553514
AHR-CDK14chr717338953chr790741857708HLA-B15:20KPVQKTLSY0.96950.7108716
AHR-CDK14chr717338953chr790741857708HLA-A02:06KTLSYVNHA0.94840.71591120
AHR-CDK14chr717338953chr790741857708HLA-B35:28KPVQKTLSY0.94610.7203716
AHR-CDK14chr717338953chr790741857708HLA-A30:01KTLSYVNHA0.94470.75751120
AHR-CDK14chr717338953chr790741857708HLA-C07:22RRKPVQKTL0.9310.7442514
AHR-CDK14chr717338953chr790741857708HLA-B35:24KPVQKTLSY0.92620.663716
AHR-CDK14chr717338953chr790741857708HLA-C07:04RRKPVQKTL0.91230.9334514
AHR-CDK14chr717338953chr790741857708HLA-C06:08RRKPVQKTL0.87010.9898514
AHR-CDK14chr717338953chr790741857708HLA-B39:02RRKPVQKTL0.86430.8809514
AHR-CDK14chr717338953chr790741857708HLA-B39:31RRKPVQKTL0.82390.8498514
AHR-CDK14chr717338953chr790741857708HLA-B18:11KPVQKTLSY0.72140.5724716
AHR-CDK14chr717338953chr790741857708HLA-B48:02KPVQKTLSY0.71580.6847716
AHR-CDK14chr717338953chr790741857708HLA-B15:11KPVQKTLSY0.62020.5945716
AHR-CDK14chr717338953chr790741857708HLA-B15:12KPVQKTLSY0.61360.641716
AHR-CDK14chr717338953chr790741857708HLA-B15:08KPVQKTLSY0.60710.5884716
AHR-CDK14chr717338953chr790741857708HLA-B35:43KPVQKTLSY0.55790.5936716
AHR-CDK14chr717338953chr790741857708HLA-C07:17KPVQKTLSY0.55660.9003716
AHR-CDK14chr717338953chr790741857708HLA-C06:06RRKPVQKTL0.50940.9931514
AHR-CDK14chr717338953chr790741857708HLA-B18:04KPVQKTLSY0.39270.6556716
AHR-CDK14chr717338953chr790741857708HLA-C03:02KPVQKTLSY0.38430.9182716
AHR-CDK14chr717338953chr790741857708HLA-C06:02RRKPVQKTL0.32350.993514
AHR-CDK14chr717338953chr790741857708HLA-C06:17RRKPVQKTL0.32350.993514
AHR-CDK14chr717338953chr790741857708HLA-B15:68RRKPVQKTL0.26570.6493514
AHR-CDK14chr717338953chr790741857708HLA-C03:67RRKPVQKTL0.25310.9822514
AHR-CDK14chr717338953chr790741857708HLA-B35:09KPVQKTLSY0.18730.7113716
AHR-CDK14chr717338953chr790741857708HLA-B18:07KPVQKTLSY0.13720.5569716
AHR-CDK14chr717338953chr790741857708HLA-B18:03KPVQKTLSY0.12880.615716
AHR-CDK14chr717338953chr790741857708HLA-B18:06KPVQKTLSY0.1260.6262716
AHR-CDK14chr717338953chr790741857708HLA-C12:02KPVQKTLSY0.03240.8955716
AHR-CDK14chr717338953chr790741857708HLA-B27:10KRRKPVQKTL0.99940.8676414
AHR-CDK14chr717338953chr790741857708HLA-B27:08KRRKPVQKTL0.99940.622414
AHR-CDK14chr717338953chr790741857708HLA-B27:06KRRKPVQKTL0.9990.7542414
AHR-CDK14chr717338953chr790741857708HLA-B27:09KRRKPVQKTL0.99530.6997414
AHR-CDK14chr717338953chr790741857708HLA-C07:01KRRKPVQKTL0.99190.5487414
AHR-CDK14chr717338953chr790741857708HLA-B15:08RKPVQKTLSY0.96710.7351616
AHR-CDK14chr717338953chr790741857708HLA-B15:11RKPVQKTLSY0.96680.7535616
AHR-CDK14chr717338953chr790741857708HLA-C07:22KRRKPVQKTL0.96170.6052414
AHR-CDK14chr717338953chr790741857708HLA-B15:53RKPVQKTLSY0.95590.7455616
AHR-CDK14chr717338953chr790741857708HLA-B35:43RKPVQKTLSY0.95450.7382616
AHR-CDK14chr717338953chr790741857708HLA-B15:54RKPVQKTLSY0.92780.7224616
AHR-CDK14chr717338953chr790741857708HLA-B35:11RKPVQKTLSY0.86550.8333616
AHR-CDK14chr717338953chr790741857708HLA-B35:30RKPVQKTLSY0.84270.5377616
AHR-CDK14chr717338953chr790741857708HLA-B35:17RKPVQKTLSY0.84270.5377616
AHR-CDK14chr717338953chr790741857708HLA-B35:77RKPVQKTLSY0.78910.7558616
AHR-CDK14chr717338953chr790741857708HLA-B35:23RKPVQKTLSY0.78320.6734616
AHR-CDK14chr717338953chr790741857708HLA-B27:10RRKPVQKTLSY0.99990.8417516
AHR-CDK14chr717338953chr790741857708HLA-B27:08RRKPVQKTLSY0.99990.5837516
AHR-CDK14chr717338953chr790741857708HLA-B27:06RKRRKPVQKTL0.99980.603314
AHR-CDK14chr717338953chr790741857708HLA-B27:10RKRRKPVQKTL0.99970.7394314
AHR-CDK14chr717338953chr790741857708HLA-C07:01RRKPVQKTLSY0.99960.5803516
AHR-CDK14chr717338953chr790741857708HLA-B27:09RKRRKPVQKTL0.99930.5573314
AHR-CDK14chr717338953chr790741857708HLA-B27:09RRKPVQKTLSY0.99930.6917516
AHR-CDK14chr717338953chr790741857708HLA-C07:22RRKPVQKTLSY0.99790.5639516
AHR-CDK14chr717338953chr790741857708HLA-C07:02RRKPVQKTLSY0.99720.9233516
AHR-CDK14chr717338953chr790741857708HLA-B15:08RRKPVQKTLSY0.98850.8062516
AHR-CDK14chr717338953chr790741857708HLA-B15:11RRKPVQKTLSY0.9880.8203516
AHR-CDK14chr717338953chr790741857708HLA-B35:43RRKPVQKTLSY0.98650.8055516
AHR-CDK14chr717338953chr790741857708HLA-B35:11RRKPVQKTLSY0.96410.8704516
AHR-CDK14chr717338953chr790741857708HLA-B35:17RRKPVQKTLSY0.95390.6222516
AHR-CDK14chr717338953chr790741857708HLA-B35:30RRKPVQKTLSY0.95390.6222516
AHR-CDK14chr717338953chr790741857708HLA-B15:54RRKPVQKTLSY0.95320.7929516

Top

Potential FusionNeoAntigen Information of AHR-CDK14 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
AHR-CDK14_17338953_90741857.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
AHR-CDK14chr717338953chr790741857708DRB1-0801QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0801VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0803QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0803VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0805QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0805VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0806QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0806VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0808QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0810QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0810VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0811QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0812QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0812VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0814QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0814VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0816QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0816VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0818QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0822QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0822VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0823QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0823VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0826QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0826VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0827QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0827VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0829QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0829VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0832QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0833QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0833VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0835QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0835VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0836QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0836VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0838QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0838VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0839QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-0839VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-0840QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-1312QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-1312VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-1313QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-1313VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-1321QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-1349QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-1349VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-1355QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-1355VQKTLSYVNHAEDLA924
AHR-CDK14chr717338953chr790741857708DRB1-1358QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-1389QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-1473QKTLSYVNHAEDLAS1025
AHR-CDK14chr717338953chr790741857708DRB1-1473VQKTLSYVNHAEDLA924

Top

Fusion breakpoint peptide structures of AHR-CDK14

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
7983RKPVQKTLSYVNHAAHRCDK14chr717338953chr790741857708

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of AHR-CDK14

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN7983RKPVQKTLSYVNHA-6.11479-7.15009
HLA-B14:023BVN7983RKPVQKTLSYVNHA-4.76706-4.88046
HLA-B52:013W397983RKPVQKTLSYVNHA-6.87405-6.98745
HLA-B52:013W397983RKPVQKTLSYVNHA-5.3619-6.3972
HLA-A11:014UQ27983RKPVQKTLSYVNHA-9.79836-9.91176
HLA-A24:025HGA7983RKPVQKTLSYVNHA-8.83847-8.95187
HLA-A24:025HGA7983RKPVQKTLSYVNHA-8.05027-9.08557
HLA-B44:053DX87983RKPVQKTLSYVNHA-7.51915-7.63255
HLA-B44:053DX87983RKPVQKTLSYVNHA-4.45384-5.48914
HLA-A02:016TDR7983RKPVQKTLSYVNHA-2.8902-3.9255

Top

Vaccine Design for the FusionNeoAntigens of AHR-CDK14

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
AHR-CDK14chr717338953chr7907418571120KTLSYVNHAGAAAACGCTCAGCTATGTGAACCATGC
AHR-CDK14chr717338953chr790741857314RKRRKPVQKTLTCGCAAGCGGCGGAAGCCGGTGCAGAAAACGCT
AHR-CDK14chr717338953chr790741857414KRRKPVQKTLCAAGCGGCGGAAGCCGGTGCAGAAAACGCT
AHR-CDK14chr717338953chr790741857514RRKPVQKTLGCGGCGGAAGCCGGTGCAGAAAACGCT
AHR-CDK14chr717338953chr790741857516RRKPVQKTLSYGCGGCGGAAGCCGGTGCAGAAAACGCTCAGCTA
AHR-CDK14chr717338953chr790741857616RKPVQKTLSYGCGGAAGCCGGTGCAGAAAACGCTCAGCTA
AHR-CDK14chr717338953chr790741857716KPVQKTLSYGAAGCCGGTGCAGAAAACGCTCAGCTA
AHR-CDK14chr717338953chr790741857816PVQKTLSYGCCGGTGCAGAAAACGCTCAGCTA
AHR-CDK14chr717338953chr790741857917VQKTLSYVGGTGCAGAAAACGCTCAGCTATGT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
AHR-CDK14chr717338953chr7907418571025QKTLSYVNHAEDLASGCAGAAAACGCTCAGCTATGTGAACCATGCAGAGGACCTGGCCTC
AHR-CDK14chr717338953chr790741857924VQKTLSYVNHAEDLAGGTGCAGAAAACGCTCAGCTATGTGAACCATGCAGAGGACCTGGC

Top

Information of the samples that have these potential fusion neoantigens of AHR-CDK14

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCAAHR-CDK14chr717338953ENST00000242057chr790741857ENST00000406263TCGA-AN-A0FY-01A

Top

Potential target of CAR-T therapy development for AHR-CDK14

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to AHR-CDK14

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to AHR-CDK14

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource